Search results
Results from the WOW.Com Content Network
[19] [20] As of 2020, he was on the board of directors or is a trustee of several organizations, including serving as chairman of the Board of the Foundation for the NIH (FNIH) [21] and as a Director of Alnylam Pharmaceuticals, [22] Sage Therapeutics, [23] Voyager Therapeutics [24] and Karuna Pharmaceuticals. [25]
She is the founder and CEO [1] of Seaport Therapeutics, [2] co-founder of Karuna Therapeutics, [3] and Founding CEO of PureTech Health. [4] She sits on the board of BIO [5] and is a co-founder and host of Biotech Hangout. [6] She was named one of the most influential people in Biopharma in 2023. [7] MIT Technology Review TR35 top innovators .
Previous logo. Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is ...
Karuna's drug is expected to be patent-protected in the United States through the mid-2030s. The deal is expected to hit Bristol Myers' earnings per share by roughly 30 cents in 2024 due to the ...
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
2016 April: The rights to develop and sell NBI-1117568 were transferred from its original developer to Allergan. [9]2017 September: Allergan initiated Phase I clinical trials for NBI-1117568 to treat "neurobehavioral symptoms related to Alzheimer's disease and other conditions."
The last image we have of Patrick Cagey is of his first moments as a free man. He has just walked out of a 30-day drug treatment center in Georgetown, Kentucky, dressed in gym clothes and carrying a Nike duffel bag.
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.